David Roman
Stock Analyst at Goldman Sachs
(1.80)
# 3,336
Out of 5,241 analysts
83
Total ratings
32.61%
Success rate
-6.93%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Neutral | $28 → $24 | $18.97 | +26.52% | 8 | May 15, 2026 | |
| GEHC GE HealthCare Technologies | Downgrades: Neutral | $81 → $65 | $60.76 | +6.98% | 5 | Apr 30, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $87 → $84 | $52.68 | +59.45% | 3 | Apr 23, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Neutral | $167 | $143.47 | +16.40% | 2 | Apr 10, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $28 → $25 | $12.82 | +95.01% | 3 | Apr 9, 2026 | |
| SYK Stryker | Maintains: Neutral | $403 → $357 | $306.76 | +16.38% | 3 | Apr 9, 2026 | |
| OMDA Omada Health | Maintains: Buy | $26 → $23 | $16.56 | +38.89% | 2 | Apr 9, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $22 → $17 | $19.82 | -14.23% | 4 | Apr 9, 2026 | |
| IRTC iRhythm Holdings | Maintains: Neutral | $184 → $147 | $114.00 | +28.95% | 5 | Apr 9, 2026 | |
| ISRG Intuitive Surgical | Maintains: Buy | $714 → $609 | $421.12 | +44.61% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $326 → $277 | $147.46 | +87.85% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $11.01 | +54.41% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $9.46 | +111.42% | 4 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $121 | $84.47 | +43.25% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $17 | $17.30 | -1.73% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $95 | $81.38 | +16.74% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $49 | $36.19 | +35.40% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $89 | $82.17 | +8.31% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $64 → $71 | $59.61 | +19.11% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $81 → $111 | $76.15 | +45.76% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $16.09 | -0.56% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $103 | $144.01 | -28.48% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $15.63 | +27.96% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $104 | $83.70 | +24.25% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $6.36 | +57.23% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $74.26 | -4.39% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $70.00 | -21.43% | 2 | Mar 3, 2025 |
Doximity
May 15, 2026
Maintains: Neutral
Price Target: $28 → $24
Current: $18.97
Upside: +26.52%
GE HealthCare Technologies
Apr 30, 2026
Downgrades: Neutral
Price Target: $81 → $65
Current: $60.76
Upside: +6.98%
Boston Scientific
Apr 23, 2026
Maintains: Buy
Price Target: $87 → $84
Current: $52.68
Upside: +59.45%
Becton, Dickinson and Company
Apr 10, 2026
Reinstates: Neutral
Price Target: $167
Current: $143.47
Upside: +16.40%
Tandem Diabetes Care
Apr 9, 2026
Maintains: Neutral
Price Target: $28 → $25
Current: $12.82
Upside: +95.01%
Stryker
Apr 9, 2026
Maintains: Neutral
Price Target: $403 → $357
Current: $306.76
Upside: +16.38%
Omada Health
Apr 9, 2026
Maintains: Buy
Price Target: $26 → $23
Current: $16.56
Upside: +38.89%
Kestra Medical Technologies
Apr 9, 2026
Maintains: Neutral
Price Target: $22 → $17
Current: $19.82
Upside: -14.23%
iRhythm Holdings
Apr 9, 2026
Maintains: Neutral
Price Target: $184 → $147
Current: $114.00
Upside: +28.95%
Intuitive Surgical
Apr 9, 2026
Maintains: Buy
Price Target: $714 → $609
Current: $421.12
Upside: +44.61%
Apr 9, 2026
Maintains: Buy
Price Target: $326 → $277
Current: $147.46
Upside: +87.85%
Apr 9, 2026
Maintains: Buy
Price Target: $19 → $17
Current: $11.01
Upside: +54.41%
Apr 9, 2026
Maintains: Buy
Price Target: $23 → $20
Current: $9.46
Upside: +111.42%
Apr 9, 2026
Maintains: Buy
Price Target: $140 → $121
Current: $84.47
Upside: +43.25%
Feb 17, 2026
Maintains: Neutral
Price Target: $21 → $17
Current: $17.30
Upside: -1.73%
Feb 11, 2026
Maintains: Buy
Price Target: $108 → $95
Current: $81.38
Upside: +16.74%
Jan 12, 2026
Initiates: Buy
Price Target: $49
Current: $36.19
Upside: +35.40%
Jan 9, 2026
Downgrades: Sell
Price Target: $89
Current: $82.17
Upside: +8.31%
Dec 8, 2025
Maintains: Sell
Price Target: $64 → $71
Current: $59.61
Upside: +19.11%
Nov 19, 2025
Upgrades: Neutral
Price Target: $81 → $111
Current: $76.15
Upside: +45.76%
Oct 1, 2025
Initiates: Neutral
Price Target: $16
Current: $16.09
Upside: -0.56%
Oct 1, 2025
Initiates: Buy
Price Target: $103
Current: $144.01
Upside: -28.48%
Aug 25, 2025
Initiates: Buy
Price Target: $20
Current: $15.63
Upside: +27.96%
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $83.70
Upside: +24.25%
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $6.36
Upside: +57.23%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $74.26
Upside: -4.39%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $70.00
Upside: -21.43%